Stay abreast of emerging data management approaches in drug development

Learn how to use practical, conversational AI to amplify the power of your biomarker-rich clinical programs with QuartzBio's Biomarker Intelligence Platform. You'll discover QuartzBio’s approach, which employs smart, automated integration of biomarker, sample, and clinical data to create a unified data ecosystem -- now amplified with the power of conversational interactions to enable more consumable insights. Read More →

The explosion of generative AI and, specifically, large language models (LLMs), has created renewed energy, focus and promise around the hype of AI impacting the R&D lifecycle. Generative AI is revolutionizing precision medicine clinical trial planning, execution, and operations. Organizations are increasingly recognizing its potential, rallying behind AI initiatives. The race is on – the race to leverage AI as a force multiplier, knowledge amplifier and value generator, ultimately accelerating time-to-insight. In this post, we explore concrete ways in which generative AI can deliver on these promises. Read More →

Discussions were lively at the “Digitization of Clinical Development & Clinical Trials” symposium at last week’s Bio-IT World conference. Addressing an audience of biotech and pharma IT and data leaders, QuartzBio’s Tobi Guennel gave a provocative presentation on how deploying generative AI can amplify the ability of precision medicine approaches to accelerate drug development. Read More →

Tobi Guennel, PhD, QuartzBio’s Senior Vice President of Product & Chief Architect, energized the Biomarkers & Precision Medicine track at SCOPE 2024 by showing how generative AI can address challenges faced biospecimen and biomarker operations teams, as well as clinical and translational teams, when gathering insights on samples across all parts of a complex biomarker data ecosystem. Read More →